Ezetimibe combined with low-dose statin effectively lowers LDL in protease inhibitor treated patients

AIDS Patient Care and STDs

Volumn 22, Issue 6, 2008, Pages 483-488

  Van Den Berg Wolf, Mary ^a   Klibanov, Olga M ^b   Gaughan, John P ^a   Tedaldi, Ellen M ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CREATINE KINASE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NELFINAVIR; PRAVASTATIN; PROTEINASE INHIBITOR; AZETIDINE DERIVATIVE; HEPTANOIC ACID DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOPINAVIR; PYRROLE DERIVATIVE; RITONAVIR;

ADULT; ANALYSIS OF VARIANCE; BIOASSAY; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG BLOOD LEVEL; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MALE; MONOTHERAPY; SMOKING; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; BLOOD; DRUG ADMINISTRATION; DRUG EFFECTS; FOLLOW UP; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; HYPERCHOLESTEROLEMIA; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AZETIDINES; CHOLESTEROL, LDL; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HEPTANOIC ACIDS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; HYPERCHOLESTEROLEMIA; LOPINAVIR; MALE; MIDDLE AGED; PILOT PROJECTS; PRAVASTATIN; PROSPECTIVE STUDIES; PYRROLES; RITONAVIR; TREATMENT OUTCOME;

EID: 47949085089     PISSN: 10872914     EISSN: None     Source Type: Journal    
DOI: 10.1089/apc.2007.0206     Document Type: Conference Paper

References (13)

1. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
2. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-1748.
3. Rickerts V, Brodt H, Staszewski S, et al. Incidence of myocardial infractions in HIV-infected patients between 1983 and 1998: The Frankfurt HIV-Cohort Study. Eur J Med Res 2000;5:329-333.
4. Knobel H, Jerico C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: Concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDs 2007;21:452-457.
5. Barrios A, Blanco F, Garcia-Benayas T, et al. Effect of dietary intervention on highly active antiretroviral therapy-related dyslipidemia. AIDS 2002;16:2079-2081.
6. Dube MP, Stein J, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adults AIDS Clinical Trials Group. Clin Infect Dis 2003;37:613-627.
7. Merck/Schering-Plough Pharmaceuticals. Zetia (ezetimibe) product information. North Wales, PA, 2005.
8. Coll B, Aragones G, Parra S, et al. Ezetimibe effectively decreases LDL-cholesterol in HIV-infected patients. AIDS 2006;20:1675-1677.
9. Wohl D, Hsue P, Richard S, et al. Ezetimibe's effects on the LDL cholesterol levels of HIV-infected patients receiving HAART [oral abstract 39]. Presented at: 14th Conference on Retroviruses and Opportunistic Infections, 2007, Los Angeles, CA.
10. Negredo E, Molto J, Puig J, et al. Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins. AIDS 2006;20:2159-2164.
11. Pearson TA, Denke MA, McBride PE, et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: A substudy of the ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 2006;81:1177-1185.
12. Benard A, Bonnet F, Tessier JF, et al. Tobacco addiction and HIV infection: Toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort. AIDS Patient Care STDs 2007;21:458-468.
13. Abbott Laboratories. Kaletra (lopinavir/ritonavir) product information. Abbott Park, IL, 2006.